No Data
No Data
Tong Ren Tang Chinese Medicine Appoints CEO
Tong Ren Tang Chinese Medicine (HKG:3613) has appointed Wang Chi as its new chief executive officer, effective May 10, according to a filing with Hong Kong Exchange last Friday. The acting CEO Chen Fe
Tong Ren Tang Sinopharm (03613) will pay a final dividend of HK$0.33 per share on June 24
According to the Zhitong Finance App, Tong Ren Tang Sinopharm (03613) announced that it will pay a final dividend of HK$0.33 per share for the year ended 31 December 2023 on June 24, 2024.
TONGRENTANGCM: Postponement and Rescheduling of Date of Annual General Meeting and Change of Book Closure Period
Tong Ren Tang Sinopharm (03613.HK) appoints Wang Chi as CEO
Gelonghui, May 10, 丨 Tong Ren Tang Sinopharm (03613.HK) announced that Mr. Wang Chi was appointed as the company's executive director, CEO and member of the Competition Executive Committee, effective May 10, 2024. The board of directors further announced that since Mr. Wang was appointed as the company's CEO, Mr. Chen Fei, executive director, acting CEO and executive deputy general manager of the company will no longer serve as acting CEO. Effective May 10, 2024, he will continue to serve as the company's executive director and executive deputy general manager.
Tong Ren Tang Chinese Medicine (03613): Issued a certificate of registration for proprietary Chinese medicines
According to Zhitong Finance App, Tong Ren Tang Sinopharm (03613) issued an announcement. The company recently received the “Certificate of Registration for Proprietary Chinese Medicines” issued by the Hong Kong Traditional Chinese Medicine Administration, which allows the sale of “Angelica Blood Supplementation Granules [Tong Ren Tang]” in Hong Kong.
Tong Ren Tang (600085.SH): “Angelica Blood Supplement Granules [Tong Ren Tang]” obtained the Hong Kong Proprietary Chinese Medicine Registration Certificate
Zhitong Finance App News, Tong Ren Tang (600085.SH) issued an announcement. Recently, Beijing Tongrentang Sinopharm Co., Ltd. (hereinafter referred to as Tongrentang Sinopharm), the company's holding company, received the “Certificate of Registration for Proprietary Chinese Medicine” issued by the Hong Kong Traditional Chinese Medicine Administration, permitting the sale of “Angelica Blood Supplement Granules [Tong Ren Tang]” in Hong Kong. According to the announcement, after receiving the registration certificate for proprietary Chinese medicines issued by the Hong Kong Traditional Chinese Medicine Administration, Tongrentang Sinopharm's angelica blood supplement granules “Tong Ren Tang” can be sold in Hong Kong, which will help enrich its product line and facilitate its market expansion. The one with the above registration certificate
No Data